TY  - JOUR
AU  - Dy Closas, Alfand Marl F
AU  - Tan, Ai Huey
AU  - Tay, Yi Wen
AU  - Hor, Jia Wei
AU  - Toh, Tzi Shin
AU  - Lim, Jia Lun
AU  - Lew, Choey Yee
AU  - Cham, Chun Yoong
AU  - Yim, Carolyn Chue Wai
AU  - Chee, Kok Yoon
AU  - Ng, Chong Guan
AU  - Lit, Lei Cheng
AU  - Anuar, Anis Nadhirah Khairul
AU  - Lange, Lara M
AU  - Fang, Zih-Hua
AU  - Ciga, Sara Bandres
AU  - Lohmann, Katja
AU  - Klein, Christine
AU  - Ahmad-Annuar, Azlina
AU  - Muthusamy, Kalai Arasu
AU  - Lim, Shen-Yang
TI  - New insights from a Malaysian real-world deep brain stimulation cohort.
JO  - Journal of Parkinson's Disease
VL  - 15
IS  - 1
SN  - 1877-7171
CY  - Amsterdam
PB  - IOS Press
M1  - DZNE-2025-00470
SP  - 1877718X241297715
PY  - 2025
AB  - BackgroundThe availability of deep brain stimulation (DBS), a highly efficacious treatment for several movement disorders, remains low in developing countries, with scarce data available on utilization and outcomes.ObjectiveWe characterized the DBS cohort and outcomes at a Malaysian quaternary medical center.MethodsA retrospective chart review was done on DBS-related surgery at the University of Malaya, including clinico-demographic, genetics, and outcomes data focusing on post-operative medication reduction and complications.Results149 Parkinson's disease (PD) patients underwent DBS targeting the subthalamic nucleus. Six had globus pallidus internus DBS (primarily for dystonia). Only 16.1
KW  - Humans
KW  - Deep Brain Stimulation
KW  - Male
KW  - Female
KW  - Middle Aged
KW  - Parkinson Disease: therapy
KW  - Retrospective Studies
KW  - Aged
KW  - Malaysia
KW  - Subthalamic Nucleus
KW  - Adult
KW  - Globus Pallidus
KW  - Glucosylceramidase
KW  - Levodopa: administration & dosage
KW  - Cohort Studies
KW  - Asia (Other)
KW  - EARLYSTIM (Other)
KW  - GBA1 (Other)
KW  - LRRK2 (Other)
KW  - Parkinson's disease (Other)
KW  - access to care (Other)
KW  - deep brain stimulation (Other)
KW  - dystonia (Other)
KW  - genetics (Other)
KW  - subthalamic nucleus (Other)
KW  - Glucosylceramidase (NLM Chemicals)
KW  - Levodopa (NLM Chemicals)
KW  - GBA protein, human (NLM Chemicals)
LB  - PUB:(DE-HGF)16
C6  - pmid:39973484
DO  - DOI:10.1177/1877718X241297715
UR  - https://pub.dzne.de/record/277792
ER  -